COMP <GO>
PRGO vs AUPH // FORWARD P/E MULTIPLE
Perrigo Company plc (NYSE) VS. Aurinia Pharmaceuticals Inc (NASDAQ) • 15-METRIC TALLY: PRGO 3
— AUPH 8
■ METRIC PARITY
LAST: $15.75 (-0.19%) • MKT CAP: $2.19B
forward-pe
—
LAST: $16.14 (-3.06%) • MKT CAP: $2.22B
forward-pe
6.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRGO VS. AUPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRGO | AUPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.10% | 88.50% | -53.40 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.60% | 16.50% | -30.10 | AUPH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.58% | 5.92% | +0.66 | PRGO | /fcf-yield <GO> |
| Operating Margin | -26.40% | 37.10% | -63.50 | AUPH | /operating-margins <GO> |
| Net Profit Margin | -33.50% | 68.00% | -101.50 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) | -2.80% | 20.40% | -23.20 | AUPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 7.22% | 0.00% | +7.22 | PRGO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 8.33 | -8.13 | AUPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | AUPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.8 | 49.1 | +5.70 | PRGO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | 6.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.19B | $2.22B | -$25.5M | AUPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRGO REV | AUPH REV | PRGO GROSS % | AUPH GROSS % | PRGO FCF | AUPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.25B | $283.1M | 35.1% | 88.5% | $145.1M | $135.7M |
| FY 2024 | $4.37B | $235.1M | 35.3% | 88.0% | $244.6M | $44.4M |
| FY 2023 | $4.66B | $175.5M | — | — | $405.5M | -$33.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRGO // BETA —
AUPH // BETA —